ALS LIMITED (ALQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALQ

ALQ - ALS LIMITED

Year End: March
GICS Industry Group : Commercial & Professional Services
Debt/EBITDA: 2.97
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

ALS Ltd provides laboratory and testing services across the mining, industrial and life sciences sector. It operates in over 65 countries. Formerly Campbell Brothers Ltd it first listed in 1952 and changed name to ALS in 2012.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$16.30

28 May
2025

-1.390

OPEN

$16.50

-7.86%

HIGH

$16.59

4,795,327

LOW

$16.00

TARGET
$18.913 16.0% upside
Franking for last dividend paid out: 30%
OTHER COMPANIES IN THE SAME SECTOR
3DA . AVD . BOL . BSA . CG1 . CLG . CVL . CWY . CXL . DOW . DUR . EGL . EGN . EVS . FLC . IPG . LBL . MAD . PPK . RWL . SDV . SHA . SND . SSM . SYL . VEE . VNT .
FNARENA'S MARKET CONSENSUS FORECASTS
ALQ: 1
Title FY24
Actual
FY25
Actual
FY26
Forecast
FY27
Forecast
EPS (cps) xxx 52.9 73.3 xxx
DPS (cps) xxx 0.0 44.2 xxx
EPS Growth xxx 100.0% 38.4% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 22.1 xxx
Dividend Yield xxx N/A 2.7% xxx
Div Pay Ratio(%) xxx N/A 60.4% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 27/11 - ex-div 18.90c (franking 30%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx52.9
DPS All xxxxxxxxxxxxxxx38.6
Sales/Revenue xxxxxxxxxxxxxxx2,999.4 M
Book Value Per Share xxxxxxxxxxxxxxx263.9
Net Operating Cash Flow xxxxxxxxxxxxxxx416.6 M
Net Profit Margin xxxxxxxxxxxxxxx8.54 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx20.80 %
Return on Invested Capital xxxxxxxxxxxxxxx8.62 %
Return on Assets xxxxxxxxxxxxxxx6.52 %
Return on Equity xxxxxxxxxxxxxxx20.80 %
Return on Total Capital xxxxxxxxxxxxxxx14.58 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx74.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx164 M
Long Term Debt xxxxxxxxxxxxxxx1,929 M
Total Debt xxxxxxxxxxxxxxx2,093 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx268 M
Price To Book Value xxxxxxxxxxxxxxx5.84

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx165.0 M
Capex % of Sales xxxxxxxxxxxxxxx5.50 %
Cost of Goods Sold xxxxxxxxxxxxxxx2,058 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx471 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx37 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.9

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

28/05/2025

-1

No Rating

-

ALS Ltd's FY25 revenue was down -1% y/y and in line with recent guidance range, but lower than Macquarie's forecast. EBIT for life sciences division beat the broker's forecast but commodities missed.

The broker expects the environmental division within life sciences to outperform, contributing to 20-40bps margin improvement in FY26. In the case of commodities division, the analyst expects flat margin to continue in 1H26, before recovery in 2H26.

The company is doing $350m capital raise to fund expansions of its lab capacity. The broker cut FY26-27 EPS forecasts by -4% on lower commodities earnings and included $350m equity raising which it highlights is EPS neutral in FY26 due to interest cost savings.

The broker has research restriction. No rating and target price.

FORECAST
Macquarie forecasts a full year FY26 dividend of 44.00 cents and EPS of 73.40 cents.
Macquarie forecasts a full year FY27 dividend of 49.10 cents and EPS of 81.80 cents.

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Goldman Sachs

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

27/05/2025

4

Downgrade to Underweight from Neutral

$15.00

-7.98%

Jarden downgrades ALS Ltd to Underweight from Neutral due to the run-up in the share price, which is currently reflecting earnings upgrades, according to the analyst.

Research was issued before the company was due to report FY25 results today, with guidance for net profit after tax of $310m–$313m, with Jarden positioned at the midpoint.

On balance, Jarden views the risks as slanted to the downside, with volatility in sampling flows and Bloomberg capital raising data indicating the commodity markets were down in Canada by -28% and Australia down -40% following a robust 3Q25.

Target price lifts slightly to $15 from $14.50.

FORECAST
Jarden forecasts a full year FY26 dividend of 42.80 cents and EPS of 72.40 cents.

ALQ STOCK CHART